Form 8-K/A - Current report: [Amend]
SEC Accession No. 0000950170-21-000831
Filing Date
2021-08-05
Accepted
2021-08-04 19:20:58
Documents
18
Period of Report
2021-06-25
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A cmpx-20210625.htm   iXBRL 8-K/A 47149
2 EX-23.1 cmpx-20210625ex23_1.htm EX-23.1 4234
3 EX-99.1 cmpx-20210625ex99_1.htm EX-99.1 317385
4 EX-99.2 cmpx-20210625ex99_2.htm EX-99.2 376262
5 EX-99.3 cmpx-20210625ex99_3.htm EX-99.3 363745
6 GRAPHIC img123342970_0.jpg GRAPHIC 3485
7 GRAPHIC img122419449_0.jpg GRAPHIC 3485
  Complete submission text file 0000950170-21-000831.txt   1302420

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cmpx-20210625.xsd EX-101.SCH 2474
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cmpx-20210625_lab.xml EX-101.LAB 14570
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cmpx-20210625_pre.xml EX-101.PRE 10783
11 EXTRACTED XBRL INSTANCE DOCUMENT cmpx-20210625_htm.xml XML 5029
Mailing Address 80 GUEST STREET BOSTON MA 02135
Business Address 80 GUEST STREET BOSTON MA 02135 617-500-8099
Compass Therapeutics, Inc. (Filer) CIK: 0001738021 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39696 | Film No.: 211145716
SIC: 2836 Biological Products, (No Diagnostic Substances)